Fresenius Kabi To Build ‘One Of The Largest Sterile Injectable Manufacturing Networks In US’
Alliance With Phlow Will Strengthen American Resilience To Public Health Crises
Stating the importance of the US sterile injectables market for Fresenius Kabi, Matt Kuhn, senior director of external communications, talks to Generics Bulletin about the company’s plans to build one of the largest sterile injectable manufacturing networks in America. Meanwhile Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi in the US, talks about supply reliability in biosimilars.
You may also be interested in...
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”